BeOne Medicines SVP, General Counsel Chan Henry Lee sells 1,669 ADS for $542,425 under 10b5-1 planPUBT·Jul 24 at 03:51 PMONC-1.57%
BeOne to invest $300m in US manufacturing facility expansionPharmaceutical Technology·Jul 24 at 04:23 AMONC-1.57%
The Great Biotech Reckoning: When AI and Gene Editing Meet Wall Street's Patience in 2026Global Report·Jul 19 at 04:13 AMAMGN0.00%CRSP+1.68%
BeOne Medicines CEO John Oyler reports disposal of shares worth $75.72 millionPUBT·Jul 17 at 04:31 PM061600.00%BGNE0.00%
The Market's Island of Misfit Toys: Stop Pretending and Start BuildingGlobal Report·Jul 17 at 04:12 AMRGLD+3.87%CRMD+4.17%
BeOne Medicines to Announce Second Quarter 2026 Financial Results on August 5 | ONC Stock NewsStockTitan·Jul 16 at 09:01 PMONC-1.57%
BeOne Medicines CEO John Oyler disposes of $27,267,619 in common sharesPUBT·Jul 14 at 08:26 PMONC-1.57%
BeOne Medicine shares are trading higher after Jefferies upgraded the stock from Hold to Buy and raised its price target from $333 to $380.benzinga_article·Jul 13 at 06:38 AMONC-1.57%
Macquarie Raises BEONE MEDICINES TP to HKD257, Reiterates Outperform RatingAASTOCKS News·Jul 13 at 03:20 AMONC-1.57%061600.00%
Analyst Reiterates Buy on BeiGene, Lifts Brukinsa-Driven Outlook and Raises Price Target to $380 Amid Pipeline ProgressTip Ranks·Jul 12 at 07:25 PM061600.00%688235+1.70%
BeOne Medicines SVP, General Counsel Chan Henry Lee disposes of USD 200,833.44 in common sharesPUBT·Jul 10 at 03:45 PMONC-1.57%
BeOne Medicines Advances Minority-Focused Cancer Trial With Tislelizumab ComboTip Ranks·Jul 9 at 11:32 AM061600.00%ONC-1.57%
